Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

68
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
68
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

1.9K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
1.9K
Rational Dosage Regimen: Maintenance Dose and Loading Dose01:24

Rational Dosage Regimen: Maintenance Dose and Loading Dose

3.9K
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady...
3.9K
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance01:23

Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance

96
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
96
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.3K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.3K
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

3.5K
A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementing Timely Germline Genetic Testing for Patients With Pancreatic Cancer Using a Genetics Copilot for Point-of-Care Education and Health Assessment.

JCO precision oncology·2026
Same author

Implementation and Evaluation of a Cancer Immunotherapy Elective for Medical Students: Mixed Methods Descriptive Study.

JMIR medical education·2026
Same author

Multimodal management of PD-L1 positive sinonasal inverted papilloma with malignant transformation.

World journal of otorhinolaryngology - head and neck surgery·2025
Same author

Cutaneous Reactions to Iron Infusions: A Case Report and Clinical Review.

EJHaem·2025
Same author

Low-dose nivolumab for extranodal natural killer/T-cell lymphoma, nasal type.

EJHaem·2024
Same author

Mixed autoimmune hemolytic anemia as the initial presentation of systemic lupus erythematosus: A case report and review.

EJHaem·2024

Related Experiment Video

Updated: Jun 10, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K

Acute myeloid leukemia presenting with hepatic dysfunction: Should induction be dose reduced?

Satish Maharaj1, Simone Chang1

  • 1Hematology/Oncology, Department of Oncologic Sciences University of South Florida Tampa Florida USA.

Ejhaem
|October 17, 2024
PubMed
Summary

Medically fit patients with acute myeloid leukemia (AML) and liver dysfunction can often tolerate intensive induction therapy. Dose reduction of anthracyclines may decrease survival and remission rates in these AML patients.

Keywords:
anthracyclinehepaticleukemiamyeloidpharmacology

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

37
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K

Related Experiment Videos

Last Updated: Jun 10, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.1K
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:39

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

37
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
14:51

Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype

Published on: June 17, 2022

3.2K

Area of Science:

  • Hematology
  • Hepatology
  • Oncology

Background:

  • De novo hepatic dysfunction combined with acute myeloid leukemia (AML) in medically fit patients poses a clinical challenge.
  • Patients may present with obstructive jaundice, hepatosplenomegaly, and myeloid sarcomas impacting the biliary system.
  • Current guidelines suggest anthracycline dose reduction for hepatic dysfunction, potentially impacting treatment efficacy.

Purpose of the Study:

  • To evaluate the safety and efficacy of intensive induction therapy in medically fit AML patients with hepatic dysfunction.
  • To determine if standard anthracycline dosing can be safely administered without significant toxicity in this patient population.

Main Methods:

  • Case review and literature synthesis.
  • Analysis of treatment outcomes and toxicity in AML patients with co-existing hepatic dysfunction.

Main Results:

  • Intensive induction therapy, including standard anthracycline doses, was well-tolerated in a medically fit patient with hepatic dysfunction.
  • Literature suggests that some medically fit patients with hepatic dysfunction may benefit from intensive therapy without increased toxicity.

Conclusions:

  • Medically fit AML patients with hepatic dysfunction may not require anthracycline dose reduction.
  • Intensive induction chemotherapy can be a viable and effective treatment option for select AML patients with liver dysfunction, challenging current guideline recommendations.